TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update May 10, 2023
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease May 9, 2023
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting May 3, 2023
TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies March 21, 2023
TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones March 8, 2023
TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors January 23, 2023